Social Media Ideas for Biosimilars

Understanding How ‘Biosimilar’ Drugs Can Expand Access and Affordability

(StatePoint) Biological drug products (biologics) — which can be made of sugars, proteins, living cells, tissues, or a combination of these — are providing new options for patients...

Biosimilars Boast Big Savings But Face IP Risks, Report Says

There are no biosimilar drugs in development for 90% of biologic products set to lose their patent exclusivity by 2034, according to a report released Thursday by the Association f...

Nothing to See Here: FDA Issues Interchangeable Biosimilars Strategy Document

Nothing to See Here: FDA Issues Interchangeable Biosimilars Strategy Document Anonymous (not verified) Fri, 09/25/2026 - 00:58 pharmagather item url Nothin...

Nothing to See Here: FDA Issues Interchangeable Biosimilars Strategy Document

By Sara W. Koblitz —

Biosimilars in Brazil: Intellectual Property, Regulatory and Market Landscape

Biological drugs, or biologics, are now a well-established class of therapeutic products worldwide. Unlike conventional small-molecule drugs, which are generally obtained through c...

The Spinoff: How Biosimilars Are Becoming Wholesalers' Next Hit Show

By Bryce Platt, PharmD For more than a decade, the answer to “Where do drug wholesalers make their money?” has been generic drugs. Although wholesaler revenues are linked mo...

New Biosimilar Legislation Addresses Inflation Reduction Act Delay Provision

Key Update The Biosimilars Access and Affordability Act has been reintroduced in both chambers, which would create clearer criteria for delaying Medicare price negotiation of a re...

The Private Label Biosimilar Paradox in Medicare Part D

By Tyler Novotny and Bryce Platt PBM-affiliated private label biosimilars would seem to have a built-in formulary advantage. But for ustekinumab, that advantage has not carrie...

Biologics Standards for Innovation, Quality and Access

This GEN Spotlight on Biologics Standards for Innovation, Quality and Access brings together experts from across biopharma, standards development, and analytical science to examine...

Navigating A Key Inflection Point In Biosimilar Sector M&A

As biosimilar mergers and acquisitions gain notice amid U.S. Food and Drug Administration reforms, a maturing patent framework and a looming patent cliff, companies diversifying in...

Generic MS therapies show greater variability in disease biomarkers

Generic medications are expected to be equivalent to their brand-name counterparts — but a new study found that generic versions of certain treatments for multiple sclerosis (MS) w...

<![CDATA[FDA Approves Subcutaneous Induction for Skyrizi in Crohn's Disease]]>

Genentech, Novartis Sue Amneal Over Bid To Sell Xolair Copy

Genentech Inc. and Novartis Pharmaceuticals Corp. have filed a patent infringement suit in Delaware federal court, claiming Kashiv BioSciences' bid to sell a biosimilar copy of the...

Companies join forces to commercialize proposed biosimilar

Alvotech and Lotus Pharmaceutical are teaming up on plans to commercialize AVT87, a proposed biosimilar to Hemlibra (emicizumab). Lisa Graver, CEO of Alvotech, said in a company pr...

<![CDATA[Licensing Roundup: Biohaven & SK Biopharmaceuticals Enter Deal for BHV-7000, Haisco License’s Sentivera...

Support the Original

Okuda DT, Anderson BJ, Taylor SM, Jones-McCreary MC, Burgess KW, Wright CM, Santoyo JR, Sguigna PV, Stüve O, Tran DH, Light DY, Moog TM, Punnen TG. Comparative multi-analyte serum...

FDA clears first generic radioligand drug; Sionna turns to layoffs

A Lutathera copycat has become the first “radioligand equivalent” cleared by regulators. Elsewhere, Novo dropped the “Nordisk” from its name and a novel RNAi drug showed early prom...

Waltz Health, Fresenius Kabi partner for direct-to-payer biosimilar program

Digital health company Waltz Health is teaming up with drugmaker Fresenius Kabi to support direct-to-employer efforts for key biosimilar medications.

<![CDATA[Regeneron and Sanofi Expand Antibody Alliance with Four New Drugs]]>

Teva claims success in celiac study; BioMarin, Ascendis settle patent dispute

Teva believes the therapy has “pipeline-in-a-product” potential. Elsewhere, a high-stakes trial was paused and GSK advanced a competitor to Moderna’s flu shot.

Trailing rivals, AbbVie scores win with dual-acting myeloma drug

The drugmaker is leaning on a better side effect profile compared to drugs from J&J, Pfizer and Regeneron as it pushes etentamig toward FDA submission.

Janssen Secures Temporary Block Against Arthritis Biosimilar

A Delaware federal judge has blocked Accord BioPharma from manufacturing a biosimilar version of Janssen's arthritis treatment Simponi while the Johnson & Johnson unit's patent...

<![CDATA[Roundup: FDA Approves Lilly’s Olumiant, AbbVie’s Juvmo, Mirum & Incyte’s Atebrioz ]]>

Subcutaneous infliximab may be ‘more effective’ after drug holiday

NASHVILLE, Tenn. — Antidrug antibodies did not appear to negatively affect outcomes in patients with inflammatory bowel disease after initiation of subcutaneous infliximab followin...